Document is current
Any future updates will be listed below
-
Authors
Horner, David https://orcid.org/0000-0002-0200-4561
Jepsen, Jens Richardt M.
Chawes, Bo
Aagaard, Kristina
Rosenberg, Julie B.
Mohammadzadeh, Parisa
Sevelsted, Astrid
Vahman, Nilo
Vinding, Rebecca
Fagerlund, Birgitte https://orcid.org/0000-0003-4547-2944
Pantelis, Christos https://orcid.org/0000-0002-9565-0238
Bilenberg, Niels
Pedersen, Casper-Emil T. https://orcid.org/0000-0003-2540-5373
Eliasen, Anders https://orcid.org/0000-0003-2629-0790
Brandt, Sarah
Chen, Yulu
Prince, Nicole https://orcid.org/0000-0002-8506-1122
Chu, Su H. https://orcid.org/0000-0002-6345-008X
Kelly, Rachel S. https://orcid.org/0000-0003-3023-1822
Lasky-Su, Jessica
Halldorsson, Thorhallur I.
Strøm, Marin
Strandberg-Larsen, Katrine
Olsen, Sjurdur F.
Glenthøj, Birte Y. https://orcid.org/0000-0003-3056-7262
Bønnelykke, Klaus https://orcid.org/0000-0003-2003-1018
Ebdrup, Bjørn H.
Stokholm, Jakob https://orcid.org/0000-0003-4989-9769
Rasmussen, Morten Arendt https://orcid.org/0000-0001-7431-5206
-
Funding
Funding for this research was provided by:
Lundbeckfonden (R269-2017-5, R269-2017-5, R269-2017-5, R269-2017-5, R269-2017-5, R269-2017-5, R269-2017-5)
- License Information
-
More Information
Article History
Received: 1 September 2024
Accepted: 6 February 2025
First Online: 3 March 2025
Ethics statement
: The study is conducted in accordance with the Declaration of Helsinki and was approved by the Danish Ethics Committee (H-B-2008-093) and the Danish Data Protection Agency (2015-41-3696). The study is conducted and monitored in accordance with the requirements of GCP as defined in guidelines, EU Clinical Trials Directive (2001/20/EC) and EU GCP Directive (2005/28/EC). All study participants have signed approved informed consent forms before any study-related procedures. The confidentiality of all study participants will be protected in accordance with GCP guidelines.
: B.E. is part of the Advisory Board of Eli Lilly Denmark A/S, Janssen-Cilag, Lundbeck Pharma A/S, and Takeda Pharmaceutical Company; and has received lecture fees from Bristol-Myers Squibb, Boehringer Ingelheim, Otsuka Pharma Scandinavia AB, Eli Lilly Company and Lundbeck Pharma A/S. B.Y.G. has been the leader of a Lundbeck Foundation Centre of Excellence for Clinical Intervention and Neuropsychiatric Schizophrenia Research (CINS) (January 2009 to December 2021), which was partially financed by an independent grant from the Lundbeck Foundation based on international review and partially financed by the Mental Health Services in the Capital Region of Denmark, the University of Copenhagen and other foundations. All grants are the property of the Mental Health Services in the Capital Region of Denmark and administered by them. She has no other conflicts to disclose. J.L.-S. is a scientific advisor for Precion and a consultant to Tru Diagnostic. All other authors declare no competing interests. The funding agencies did not have any role in design and conduct of the study; collection, management and interpretation of the data; or preparation, review or approval of the paper. No pharmaceutical company was involved in the study.
